Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Withdrawn 2Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 11fludarabine phosphate 10Rituximab 6Peripheral Blood Stem Cell Transplantation 6Cytarabine 6fludarabine 5Vincristine 4Radiotherapy 4Etoposide 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3tisagenlecleucel 2blinatumomab 2Vorinostat 2Prednisone 2Pentetic Acid 2Methylprednisolone 2Melphalan 2Drug Therapy 2Doxorubicin 2Cord Blood Stem Cell Transplantation 2Carmustine 2CT-P10 2Busulfan 2Bortezomib 2Biopsy 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Burkitt Lymphoma × tisagenlecleucel × Clear all
NCT04156659 2023-03-09

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Novartis

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma

NCT02167360 2017-02-14

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡